AEON Biopharma, Inc. (NASDAQ:AEON) Expected to Post Q1 2025 Earnings of ($0.29) Per Share

Posted by Latisha Jones on Apr 20th, 2024

AEON Biopharma, Inc. (NASDAQ:AEON – Free Report) – Investment analysts at HC Wainwright issued their Q1 2025 earnings estimates for AEON Biopharma in a research report issued on Wednesday, April 17th. HC Wainwright analyst D. Tsao expects that the company will post earnings per share of ($0.29) for the quarter. HC Wainwright currently has a “Buy” rating and a $18.00 target price on the stock. The consensus estimate for AEON Biopharma’s current full-year earnings is ($1.54) per share. HC Wainwright also issued estimates for AEON Biopharma’s Q2 2025 earnings at ($0.31) EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.24) EPS.

AEON Biopharma Stock Performance

AEON opened at $4.66 on Thursday. AEON Biopharma has a twelve month low of $3.37 and a twelve month high of $17.17. The firm’s 50-day moving average price is $10.55 and its 200 day moving average price is $7.77.

AEON Biopharma (NASDAQ:AEON – Get Free Report) last announced its earnings results on Friday, March 29th. The company reported ($0.71) earnings per share (EPS) for the quarter.

Hedge Funds Weigh In On AEON Biopharma

Institutional investors and hedge funds have recently bought and sold shares of the business. Northern Trust Corp boosted its position in AEON Biopharma by 53.4% during the fourth quarter. Northern Trust Corp now owns 49,819 shares of the company’s stock worth $359,000 after acquiring an additional 17,341 shares during the last quarter. Formidable Asset Management LLC acquired a new position in AEON Biopharma during the third quarter worth about $360,000. Vanguard Group Inc. acquired a new position in AEON Biopharma during the third quarter worth about $1,085,000. Finally, Atalaya Capital Management LP acquired a new position in AEON Biopharma during the third quarter worth about $19,827,000. 22.78% of the stock is currently owned by institutional investors and hedge funds.

AEON Biopharma Company Profile

(Get Free Report)

AEON Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed a Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine.